McKesson Corporation (MCK) Presents at Bank of America Global Healthcare Conference 2026 Transcript

McKesson said it finished fiscal 2026 with strong momentum, including 15% full-year adjusted operating profit growth and 18% EPS growth, both above its long-range targets. The company also reported a strong fourth quarter with revenue growth and double-digit adjusted operating profit growth in 3 of 4 segments. Management said North American pharmaceutical distribution continues to see stable and growing utilization.

Analysis

The key signal is not just that the distribution franchise is still comping well, but that the mix is likely becoming more durable: stable-to-rising utilization usually means prescription volume is broadening beyond a single therapeutic class, which is far harder to reverse than temporary pricing tailwinds. That matters because it supports operating leverage in a business where fixed network density and procurement scale do most of the work; incremental volume should continue to fall through at attractive margins over the next 2-3 quarters.

Second-order beneficiaries are the upstream and downstream legs of the pharma supply chain. Higher, steadier throughput improves purchasing power and service-level reliability, which can pressure smaller regional distributors and specialty service providers that lack the balance-sheet capacity to absorb working-capital swings. If utilization remains firm into the second half of the year, the more interesting read-through may be to healthcare services names tied to medication access and fulfillment rather than to drug manufacturers themselves.

The main risk is that the market may already be underwriting this as a ‘quality compounding’ story and missing how sensitive the setup is to payer pressure or a normalization in specialty mix. If utilization decelerates even modestly, the earnings elasticity can compress quickly because the stock is likely priced for sustained high-single to low-double-digit growth, not just stability. Watch for any sign that gross profit growth is relying on mix rather than true volume, because that is the first place the narrative can crack over the next 1-2 quarters.

Contrarian angle: consensus likely treats the business as defensive, but the better framing is cyclical-quality with operating leverage. That means the stock can rerate upward if the market believes the growth algorithm is extending, yet it can also de-rate sharply if investors conclude the current run-rate is peak-normalized rather than structurally higher. The setup favors owning into evidence, not ahead of it.

Key Decisions for Investors

• Add to MCK on any 3-5% pullback over the next 2-4 weeks; risk/reward favors a continuation move if utilization stays firm, with downside limited by recurring volume and scale economics.
• Buy MCK Jan-2027 call spreads, funded partially by selling farther OTM calls; this expresses a 6-12 month rerating view with defined premium outlay if the market reprices sustained double-digit AOP growth.
• Pair long MCK / short a smaller-cap distributor or pharmacy-services peer with weaker scale economics for 1-2 quarters; the thesis is that stable utilization rewards network density and procurement power first.
• If next quarter shows any mix-driven earnings upside without volume confirmation, trim 25-30% of the position; that would reduce the chance of owning a late-cycle multiple peak.
• Use MCK as a defensive healthcare compounder only if broad-market volatility rises, but avoid chasing after a large gap-up because the stock is more vulnerable to guidance skepticism than the headline tone implies.